Pharmacology, Toxicology and Pharmaceutical Science
Therapeutic Drug Monitoring
100%
Multi-Drug-Resistant Tuberculosis
97%
Drug Resistant Tuberculosis
82%
Pharmacokinetics
78%
Bedaquiline
59%
Linezolid
52%
Rifampicin
49%
Extensively Drug-Resistant Tuberculosis
48%
Infection
40%
Mycobacterium Tuberculosis
39%
Cystic Fibrosis
37%
Adverse Event
37%
Tuberculostatic Agent
36%
Tobramycin
31%
Disease
30%
Isoniazid
29%
Amikacin
28%
Moxifloxacin
27%
Antibiotic Agent
27%
Mixed Infection
26%
Delamanid
24%
Drug Resistance
22%
Quinolone Derivative
22%
Lung Tuberculosis
22%
Tolerability
20%
Pharmacodynamics
19%
Dry Powder Inhaler
19%
Ertapenem
18%
Biological Marker
17%
Pharmacokinetics
17%
HIV
17%
Cohort Study
15%
Clavulanic Acid
14%
Elimination
14%
Pyrazinamide
13%
Coronavirinae
13%
Meropenem
13%
Kanamycin
13%
Levofloxacin
13%
Cotrimoxazole
12%
Pharmacokinetic Modeling
12%
Tuberculosis
12%
Carbapenem Derivative
12%
Adverse Drug Reaction
12%
Colistimethate
12%
Hospital Infection
11%
Normal Human
11%
Azithromycin
11%
Antiinfective Agent
10%
Bronchiectasis
10%
Medicine and Dentistry
Multidrug Resistant Tuberculosis
68%
Drug Resistant Tuberculosis
61%
Therapeutic Drug Monitoring
41%
Bedaquiline
40%
Tuberculosis Treatment
37%
Lung Tuberculosis
36%
Extensively Drug Resistant Tuberculosis
34%
Delamanid
28%
Infection
25%
Disease
24%
Meta-Analysis
24%
Rifampicin
23%
COVID-19
22%
Diagnosis
21%
Adverse Event
21%
Systematic Review
20%
Mixed Infection
17%
Patient with Cystic Fibrosis
17%
Mycobacterium Tuberculosis
17%
Tuberculostatic Agent
17%
Drug Resistance
16%
Public Health
16%
Odds Ratio
16%
Linezolid
15%
Tobramycin
15%
Cystic Fibrosis
15%
Health Care Cost
14%
Tuberculosis
14%
Sputum Culture
14%
Rehabilitation Engineering
14%
Drug Therapy
14%
Clavulanic Acid
13%
Meropenem
13%
Drug Sensitivity
13%
Prevalence
13%
Quinolone Derivative
13%
Patient-Data
13%
Human Immunodeficiency Virus
12%
Culture Conversion
11%
Lung Transplantation
11%
Biological Marker
11%
e-Health
11%
Carbapenemase Producing Enterobacteriaceae
11%
Azithromycin
11%
Patient Care
11%
Antibiotics
10%
Pulmonary Rehabilitation
10%
Silo-Filler's Disease
9%
Sputum Smear
9%
Sequela
9%
Keyphrases
Multidrug-resistant Tuberculosis (MDR-TB)
58%
Tuberculosis
53%
Bedaquiline
39%
Therapeutic Drug Monitoring
36%
Delamanid
25%
Restricted Sampling
23%
Tuberculosis Treatment
22%
Adverse Events
22%
Tuberculosis Patients
22%
Linezolid
21%
Rifampicin-resistant Tuberculosis
18%
Adult Patients
18%
Tobramycin
18%
Mycobacterium Tuberculosis (M. tb)
17%
Cystic Fibrosis
17%
Lung Transplantation
17%
Pharmacokinetics
16%
Rifampicin
15%
Moxifloxacin
14%
Anti-tuberculosis Drugs
14%
Pulmonary Tuberculosis
14%
Extensively Drug-resistant Tuberculosis
13%
Multidrug-resistant
13%
Inhalation
12%
COVID-19
12%
Netherlands
12%
Treatment Outcome
12%
Population Pharmacokinetic Model
12%
Tolerability
12%
Europe
11%
Pulmonary Infection
11%
Azithromycin
11%
Pharmacokinetic Evaluation
11%
Inhaled Dry Powder
11%
Carbapenems
10%
Pyrazinamide
9%
Risk Factors
9%
Cyclops
8%
Treatment Efficacy
8%
Meta-analysis
7%
Area under the Concentration-time Curve
7%
TB Drugs
7%
Anti-TB
7%
TB Treatment
7%
Drug Susceptibility Testing
7%
Malnutrition
6%
Pharmacodynamics
6%
Tuberculosis Infection
6%
Respiratory Infection
6%
Forced Expiratory Volume in 1 Second (FEV1)
6%
